Ceco Environmental Earnings Call: Key Takeaways
CECO delivered record Q3 results with revenue doubling to $404 million, driven by the Thermon acquisition and 30% organic growth, while providing aggressive 2027 guidance.
- Call
- Nov 9, 2026, 8:30 AM ET
ALFA USA Filings
Every alert, straight from SEC EDGAR
Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Filing type
Alerts
Time
2,359 alerts with these filters
CECO delivered record Q3 results with revenue doubling to $404 million, driven by the Thermon acquisition and 30% organic growth, while providing aggressive 2027 guidance.
Monroe Capital Enhanced Corporate Lending Fund completed private offerings of Class S and Class D common shares along with promissory notes to 110 accredited investors, raising approximately $152,000 in net proceeds. In connection with these offerings, the Fund reached its minimum shareholder threshold and terminated its existing escrow agreement with U.S. Bank and other parties as the escrow arrangement was no longer required.
Oncolytics Biotech announced translational data from a Phase 1b/2 trial evaluating pelareorep in patients with relapsed/refractory multiple myeloma. Single-cell sequencing demonstrated that pelareorep engaged the immune system, remodeled the tumor microenvironment, and increased populations of CD8 effector memory T cells. The data, which showed greater T cell expansion in clinical responders, will be presented at the 68th ASH Annual Meeting.
Exascale Labs Holdings Inc. entered into a firm order to purchase 16 Intel BHS 10U GPU servers equipped with NVIDIA HGX B300 GPUs from Compal Electronics for $9.04 million. The purchase is part of a larger framework agreement allowing the company to acquire up to 128 servers for a total potential value of $72.32 million through March 2027. This acquisition represents a material investment in the company's physical high-performance computing infrastructure.
Werewolf Therapeutics announced new clinical data from its Phase 1/1b trial of WTX-124 and Phase 1b/2 trial of WTX-330 for the treatment of solid tumors at the SITC 2026 Annual Meeting. WTX-124 demonstrated durable antitumor activity, including a complete response in a patient with cutaneous squamous cell carcinoma, and the company aligned with the FDA on a recommended Phase 2 dose of 18 mg. WTX-330 was reported as well-tolerated with evidence of monotherapy clinical activity in advanced, treatment-refractory disease.
Nkarta announced positive initial clinical data from its Ntrust program evaluating NKX019, an allogeneic CAR NK cell therapy, for myositis and systemic sclerosis. In the 4 billion cells per dose cohort, 83% of myositis patients achieved moderate or major responses, while 86% of systemic sclerosis patients achieved an rCRISS-25 response or greater. The therapy demonstrated a favorable safety profile with no cases of CRS, ICANS, or GvHD across 40 treated patients.
Surgery Partners entered into an amendment to its merger agreement with HealthSpan Partners (an affiliate of Bon Secours Mercy Health), increasing the cash consideration to $25.00 per share. The deal includes a 'ticking fee' of up to $1.61 per share if closing is delayed past March 1, 2027, bringing the total enterprise value to approximately $6.0 billion. The amendment follows an unsolicited $28.00 per share competing proposal from a third party, which the board determined was less favorable due to regulatory and closing certainty provided by HealthSpan.
“We are pleased to have reached this outcome, which reflects the rigorous focus of our Board of Directors and Special Committee throughout this process on delivering the best possible result for Surgery Partners and our stockholders. This transaction provides exceptional value for our stockholders, along with regulatory certainty and a closing expected in the near term.”
Eric Evans, Chief Executive Officer of Surgery Partners
Fox Corporation completed the acquisition of Roku, Inc. on November 6, 2026, for a combination of cash and FOX Class A Common Stock. This filing provides the required historical financial statements of Roku and pro forma financial information following the consummation of the transaction. Fox expects to realize synergies and operational efficiencies from the integration of Roku's streaming platform into its media business.
Inflection Point Acquisition Corp. VI provided a status update on its pending merger with Quantum Space, LLC, announcing a Virtual Analyst Day to discuss the company's technology platform and mission pipeline. Upon completion of the business combination, the combined company is expected to list on the NYSE under the ticker symbol QSPC.
Veradermics announced positive 12-month topline results from Part B of its Phase 2/3 Study '302' evaluating VDPHL01 for male pattern hair loss. The data showed significant increases in non-vellus hair counts and high rates of patient-reported visible improvement with no new safety signals. These results support a potential FDA submission for the first non-hormonal oral treatment for pattern hair loss in nearly 30 years.
Faeth Therapeutics announced topline clinical data from its Phase 2 PIK-201 trial evaluating its product candidate PIKTOR in patients with advanced endometrial cancer. The trial evaluated PIKTOR (a combination of serabelisib and sapanisertib) in combination with paclitaxel. The company released a corporate presentation detailing these preliminary efficacy and safety results to investors.
Innovative Industrial Properties amended its existing at-the-market (ATM) offering program to add its 9.25% Series B Cumulative Redeemable Preferred Stock to the facility. The program allows for the sale of common and preferred shares with an aggregate offering price of up to $500 million, of which approximately $336.9 million remains available for future issuance.
Aptevo Therapeutics presented new preclinical data for its multispecific platform candidates APVO451, APVO452, and APVO711 at the SITC 2026 Annual Meeting. The data demonstrated the molecules' ability to activate immune pathways and promote tumor-cell killing even under immunosuppressive conditions typical of solid tumors. These findings support the continued development of the company's portfolio of CD40-stimulating cancer immunotherapies.
Vir Biotechnology announced positive topline results from its pivotal Phase 3 ECLIPSE 1 trial evaluating a combination of elebsiran and tobevibart for chronic hepatitis delta. The trial met its primary endpoint with a 44% response rate (undetectable virus plus ALT normalization) at Week 48 compared to 0% in the delayed treatment group, demonstrating a favorable safety profile with no treatment discontinuations.
King Resources Global, Inc., through its subsidiary Heavenly Grace, entered into three purchase agreements to acquire a total of 19 collectible items for an aggregate consideration of approximately $12.34 million. The company will settle the acquisition costs by issuing common stock at a fixed price of $0.235 per share to the seller, Grand View Assets Limited.
Mentari Therapeutics completed its merger with InMed Pharmaceuticals Inc. and began trading on Nasdaq under the ticker 'MTRI'. In connection with the closing, the company completed $490 million in private placement financings to fund its pipeline of migraine prevention biologics, including MT-001 and MT-002.
CNH Industrial has entered into a definitive agreement to sell a 70% interest in its Construction Equipment business to Kobelco Construction Machinery for $700 million in cash. The transaction values the business at an enterprise value of $1 billion and transforms CNH into a pure-play agriculture equipment company. CNH will retain a 30% minority interest in the newly formed joint venture entities.
“This transaction significantly advances CNH’s portfolio simplification and sharpens our focus on agriculture in line with our Path to 2030. As the largest pure-play agriculture machinery OEM, CNH will be better positioned than ever to invest with conviction and create value for farmers, dealers, and shareholders at every point in the cycle.”
Suzanne Heywood, Chair of the CNH Board of Directors
“As the agriculture industry moves toward recovery, this transaction strengthens CNH’s ability to invest in the products and technologies that matter most to farmers. At the same time, by creating a stronger construction equipment player, both CNH and CE JV dealers, along with their customers, will benefit from a suite of high-quality, cost-competitive construction machines that incorporate leading technology.”
Gerrit Marx, Chief Executive Officer of CNH
Quanome Technologies entered into a definitive stock purchase agreement to acquire a 5% equity stake in QAI Labs Ltd., a life sciences technology company developing an AI-enabled antibody discovery platform. In exchange for 31,579 newly issued shares of QAI Labs, Quanome will issue 6,541,236 shares of its own common stock to the seller. The transaction advances Quanome's strategic pillar of applying quantum science and AI to molecular discovery.
CVR Energy is meeting with potential lenders regarding a proposed Term Loan B secured credit facility to fund a potential acquisition of assets from Marathon Petroleum Corporation. The target assets include the St. Paul Park, Minnesota and Mandan, North Dakota refineries along with associated marketing and logistics assets.
The Children’s Place, Inc. has voluntarily filed for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of New Jersey. The company intends to conduct a court-supervised sale of substantially all its assets by the end of December 2026 with the goal of continuing as a going concern. To support operations during this process, the company has entered into a consulting agreement for inventory liquidation sales and plans to secure a new term loan facility from existing lenders.
CDT Equity Inc. received a letter from former CEO Dr. Andrew Regan and Corvus Capital Limited indicating an intent to propose a non-binding acquisition of all outstanding common stock at $2.00 per share. The Board of Directors plans to form a Special Committee of independent directors to evaluate the potential proposal and other strategic alternatives.
Strategy Inc reported that it sold 2,051,348 shares of Class A Common Stock under its at-the-market (ATM) offering program between November 2 and November 8, 2026, generating net proceeds of $283.8 million. The company utilized these proceeds to purchase 1,036 bitcoin for $81.9 million and to repurchase $188.3 million of its STRC preferred stock. As of November 8, 2026, the company holds 850,364 bitcoins acquired at an aggregate purchase price of approximately $64.16 billion.
Future Vision II Acquisition Corp. received notification from Nasdaq on November 5, 2026, confirming that the company has regained compliance with the minimum public holders requirement under Nasdaq Listing Rule 5550(a)(3). Nasdaq has determined the company now complies with the rule and has officially closed the matter.
CorMedix Inc. has entered into a definitive agreement to acquire substantially all assets of Heron Therapeutics for $145 million in cash and 14,583,333 shares of common stock. The deal adds four commercial-stage products (ZYNRELEF, APONVIE, CINVANTI, and SUSTOL) to CorMedix's institutional care portfolio and includes up to $55 million in potential earn-out payments. To fund the transaction, CorMedix secured a new $75 million senior secured term loan facility from Pharmakon Advisors.
Heron Therapeutics has entered into a definitive agreement to sell substantially all of its assets to CorMedix Inc. for $145 million in cash and 14,583,333 shares of CorMedix common stock. The deal includes Heron's commercial portfolio (ZYNRELEF, APONVIE, CINVANTI, and SUSTOL) and provides for up to $55 million in potential earn-out payments plus royalties. Heron will remain a standalone public company, using the proceeds to repay its existing debt and evaluate new strategic investments.
Viridian Therapeutics announced positive Phase 1 clinical trial results for VRDN-008, a half-life extended FcRn inhibitor, which demonstrated a 74% peak reduction in IgG and a half-life 5-6 times longer than first-generation fragments. The data supports a potential best-in-class every-eight-week subcutaneous dosing regimen, and the company plans to initiate a pivotal trial in myasthenia gravis in mid-2027.
Netcapital Inc. received an extension from Nasdaq to regain compliance with Listing Rule 5250(c)(1) regarding delinquent periodic reports. The company has been granted until February 9, 2027, to file its Form 10-K for the fiscal year ended April 30, 2026, and its Form 10-Q for the quarter ended July 31, 2026. Failure to meet this deadline will result in a delisting notification, which the company may then appeal.
INOVIO Pharmaceuticals entered into an underwriting agreement for a public offering of 58,747,235 shares of common stock and 12,681,337 pre-funded warrants. The underwriters fully exercised their option to purchase an additional 10,714,285 shares, bringing expected net proceeds to approximately $80.5 million. The capital will be used to support the company's development and commercialization of DNA medicines.
Cullinan Therapeutics announced positive interim Phase 1b/2a clinical data for velinotamig in patients with refractory systemic lupus erythematosus (SLE). The data showed that 8 of 9 evaluable patients achieved clinically meaningful reductions in disease activity, with 4 of 7 patients with high baseline proteinuria achieving a complete renal response. The therapy demonstrated a favorable safety profile with no Grade 3 or higher cytokine release syndrome or neurotoxicity.
Faeth Therapeutics reported positive topline Phase 2 results from its PIK-201 trial evaluating PIKTOR in combination with paclitaxel for advanced endometrial cancer. The trial achieved a 33% confirmed objective response rate (ORR) and a median progression-free survival of 7.4 months, supporting the company's plan to advance the program into a Phase 3 registrational trial.